Literature DB >> 30643227

Alcohol, liver disease and the gut microbiota.

Jasmohan S Bajaj1.   

Abstract

Alcoholic liver disease, which ranges from mild disease to alcoholic hepatitis and cirrhosis, is a leading cause of morbidity and mortality worldwide. Alcohol intake can lead to changes in gut microbiota composition, even before liver disease development. These alterations worsen with advancing disease and could be complicit in disease progression. Microbial function, especially related to bile acid metabolism, can modulate alcohol-associated injury even in the presence of cirrhosis and alcoholic hepatitis. Microbiota changes might also alter brain function, and the gut-brain axis might be a potential target to reduce alcoholic relapse risk. Gut microbiota manipulation including probiotics, faecal microbial transplant and antibiotics has been studied in alcoholic liver disease with varying success. Further investigation of the modulation of the gut-liver axis is relevant, as most of these patients are not candidates for liver transplantation. This Review focuses on clinical studies involving the gut microbiota in patients with alcoholic liver disease across the spectrum from alcoholic fatty liver to cirrhosis and alcoholic hepatitis. Specific alterations in the gut-liver-brain axis that are complicit in the interactions between the gut microbiota and alcohol addiction are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30643227     DOI: 10.1038/s41575-018-0099-1

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  119 in total

1.  Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Gut Microbes       Date:  2020-03-13

2.  Current Management and Future Treatment of Alcoholic Hepatitis.

Authors:  Mack C Mitchell; Thomas Kerr; H Franklin Herlong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 3.  Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?

Authors:  Lu Jiang; Bernd Schnabl
Journal:  Physiology (Bethesda)       Date:  2020-07-01

Review 4.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

Review 5.  The knowns and unknowns of treatment for alcoholic hepatitis.

Authors:  Tejasav S Sehrawat; Mengfei Liu; Vijay H Shah
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05

Review 6.  A biological framework for emotional dysregulation in alcohol misuse: from gut to brain.

Authors:  Carina Carbia; Séverine Lannoy; Pierre Maurage; Eduardo López-Caneda; Kenneth J O'Riordan; Timothy G Dinan; John F Cryan
Journal:  Mol Psychiatry       Date:  2020-12-07       Impact factor: 15.992

Review 7.  Microbiome Modulation in Liver Disease.

Authors:  Eamonn M M Quigley
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-11-06

Review 8.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

Review 9.  Role of non-Genetic Risk Factors in Exacerbating Alcohol-related organ damage.

Authors:  Natalia A Osna; Rakesh Bhatia; Christopher Thompson; Surinder K Batra; Sushil Kumar; Yeonhee Cho; Gyongyi Szabo; Patricia E Molina; Steven A Weinman; Murali Ganesan; Kusum K Kharbanda
Journal:  Alcohol       Date:  2020-06-01       Impact factor: 2.405

10.  Deficiency of Intestinal α1-2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice.

Authors:  Rongrong Zhou; Cristina Llorente; Jinling Cao; Bei Gao; Yi Duan; Lu Jiang; Yanhan Wang; Vipin Kumar; Peter Stärkel; Lars Bode; Xuegong Fan; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2020-08-02       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.